SK bioscience Co., a pharmaceutical affiliate under South Korea‘s SK Group, announced on Tuesday that it signed a contract to distribute five major vaccines from global healthcare company Sanofi S.A. in Korea.

The contract is valid until the end of 2024 and can be extended by mutual agreement. During this period, SK bioscience will be responsible for the overall distribution of Sanofi’s major vaccines in the country. The vaccines under the contract include three types of pediatric DTaP (diphtheria, tetanus, pertussis) combination vaccines (Tetraxim, Pentaxim, Hexaxim), an adult Tdap combination vaccine (Adacel Prefilled Syringe), and a meningococcal vaccine (Menactra). The market size in Korea for the five vaccines was approximately 25.9 billion won ($19.27 million) as of 2023.